Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · TENAX THERAPEUTICS, INC. (TENX)

Tenax Therapeutics pauses LEVEL-2 enrollment to amend trial criteria after Phase 3 miss

Negative Impact 4 of 5 product/contract Written later

Tenax Therapeutics temporarily paused enrollment in its LEVEL-2 Phase 3 trial of TNX-103 while it amends the enrollment criteria to target patients with lower baseline 6-minute walk distance, based on results from the LEVEL trial. The company also said it has requested a Type C meeting with the U.S. Food and Drug Administration to discuss the overall development of levosimendan. The pause delays enrollment in a pivotal trial, and the company's investor presentation states that the LEVEL trial did not meet its primary endpoint in the overall population.

Key points

  • Enrollment in LEVEL-2 is paused and may resume at each site as the amended protocol takes effect there.
  • The amendment targets patients with baseline 6-minute walk distance of 100m to 300m, or above 300m to 400m with a right atrial volume index of 25 mL/m2 or more.
  • The LEVEL trial's overall primary endpoint difference was 3.5 M (p = 0.63), according to the investor presentation attached as Exhibit 99.1, dated October 8, 2026.

The filing

CompanyTENAX THERAPEUTICS, INC. (TENX)
Form8-K, current report
Filed with the SECOct 8, 2026, 4:15 PM ET
Accession number0001193125-26-417939

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.